Skip to content

Author

A. Avallone

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Systems serology identifies differential pan-viral seroreactivity profiles associated with healthy aging and cancer

A viral exposure signature (VES) has previously been shown to predict the development of hepatocellular carcinoma (HCC) in at-risk individuals through comprehensive serological profiling using the VirScan platform. Whether cumulative antimicrobial immune histories are associated with cancer status across multiple mal...

Beatrice Cavalluzzo, Biancamaria Cembrola, Simona Mangano et al. · 0 citations
Open access Sep 2026

Prognostic stratification of patients with biliary tract cancer treated with chemoimmunotherapy: A retrospective multicenter real‐world study

A novel prognostic index for patients with locally advanced or metastatic biliary tract cancer treated with first‐line therapy with cisplatin, gemcitabine, and durvalumab is explored and validated.

M. Persano, A. Casadei-Gardini, L. Fornaro et al. · 0 citations
Open access Sep 2026

Exploring Body Composition Profiles in Patients with Gastrointestinal Cancers: A Cross-Sectional Analysis of the NUTRISCREEN Project

Body composition (BC) analysis may integrate assessment of nutritional risk in patients with gastrointestinal cancers. Applying unsupervised machine learning techniques, we derived BC profiles (BCPs) and investigated their association with malnutrition risk and quality of life. This cross-sectional analysis includes ga...

Assunta Luongo, F. D. Di Carlo, S. Coluccia et al. · 0 citations
Open access Sep 2026

Circulating tumor DNA tumor fraction as a biomarker in refractory metastatic colorectal cancer: findings from the CAVE-2 GOIM trial

Liquid biopsy guided anti-EGFR rechallenge therapy is gaining ground as a potential option for patient with refractory metastatic colorectal cancer. However, the identification of potential biomarkers to implement patient's stratification is required. The CAVE-2 GOIM trial investigated the role of rechallenge with cetu...

Davide Ciardiello, G. Martini, L. Boscolo Bielo et al. · 0 citations
Open access Aug 2026

Tislelizumab plus chemotherapy for advanced or metastatic esophageal squamous-cell carcinoma in patients with PD-L1 Tumor Area Positivity score ≥5%: a post hoc, exploratory, long-term follow-up of RATIONALE-306☆

First-line tislelizumab plus chemotherapy provided sustained and clinically meaningful efficacy benefits over placebo plus chemotherapy and was tolerable, with no new safety signals for patients with unresectable, locally advanced, or metastatic ESCC and PD-L1 TAP score ≥5%.

D. Tougeron, J. Xu, E. Raymond et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.